Ramipril delays progression of CKD in kids by antiproteinuric effect
The blood pressure lowering medication ramipril reduced protein excretion in children with chronic kidney disease, according to a recent study published in the Journal of the American Society of Nephrology (JASN). The investigators found that ramipril therapy lowered proteinuria by an average of 43.5%. Also, a higher degree of proteinuria lowering during the first month of treatment was linked with a lower risk of CKD progression.
The excretion of protein in the urine, or proteinuria, indicates an increased risk for kidney and heart problems, and it is known in adult patients that this risk can be lowered with medications called angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers. Both types of drugs cause blood vessel relaxation and a decrease in blood pressure. It has not been clear, however, whether these medications benefit children with proteinuria.
Sophie van den Belt and his associates analyzed data from ESCAPE trial to investigate whether intensified blood pressure control can delay the progression of chronic kidney disease (CKD) in children with the condition.
A total of 280 children with CKD stage 2-4 received a fixed dose of the ACE inhibitor ramipril and were subsequently randomized to conventional or intensified blood pressure control with antihypertensive medications. The average initial proteinuria lowering was 40.2% in the conventional blood pressure control group and 46.7% in the intensified blood pressure control group. Due to the similar initial proteinuria change in the 2 study arms, the groups were combined for further analysis.
"The results indicate that a higher initial proteinuria reduction with ACE inhibition is independently associated with long-term preservation of renal function in children with CKD. This finding suggests that proteinuria lowering is an important target in the management of pediatric CKD," said Dr. van den Belt.
The study concluded that the early antiproteinuric effect of ACE inhibition is associated with long-term preservation of renal function in children with CKD. For effective management of pediatric CKD, more emphasis should be given to proteinuria lowering.
For more reference log on to the journal
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd